Agoracom Blog Home

Posts Tagged ‘tsx’

VIDEO – With $17M In Profitable Cannabis Revenues Already, The Latest Kiaro Acquisitions Are Expected To Create $43M In Revenue & $13.7M Gross Profit

Posted by AGORACOM-JC at 4:54 PM on Friday, July 16th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:

  • ANNUAL REVENUE              $17.1M Up 230%
  • ANNUAL GROSS PROFIT     $5.1M Up 281%  
  • Q1 REVENUE                          $5.2M Up 94%
  • Q1 GROSS PROFIT                 $1.56M Up 118%

But CEO Daniel Petrov and his team of retail winners aren’t stopping there. On July 13th, $KO announced  Kiaro Acquires Hemisphere Cannabis and Adds 7 Retail and 2 Development Locations in Ontario To Become a Prominent National Cannabis Retailer with Forecasted Annual Revenues of $42.7 Million.

If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.

VIDEO – Universal PropTech (UPI: TSXV) (UPIPF: OTCQB) Talks Growing Backlog At ~ $6 Million, Organic Growth, Tier-1 Customers and More

Posted by AGORACOM-JC at 4:06 PM on Monday, July 12th, 2021
This image has an empty alt attribute; its file name is SMS-Smalljpg-1.jpg

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada. 

More than just lip service, UPI clients include:

· Federal Government facilities for over 40 years 

· Manulife 

· Brookfield 

· Billy Bishop Airport 

· University of Toronto 

· …. and many more 

The company’s backlog is now a staggering $~6 million.

This represents:

  • + $800,000 from April
  • + $3,000,000 swing from September

This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.

We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally. | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

VIDEO – POET Technologies $ $POETF Describes OFC Conference as an “Inflection Point”

Posted by AGORACOM-JC at 4:47 PM on Monday, June 14th, 2021

POET Technologies (PTK: TSXV) (POETF: OTCQX) Vivek Rajgarhia, Thomas Mika and I discuss the success of their demos at the  2021 Optical Fiber Communication Conference and Exhibition (OFC) .

POET hosted a Gold-level sponsored booth showcasing the company’s latest news, products and video demonstrations.

Vivek describes the conference as an “inflection point” … and the smiles on their faces are hard to ignore! 

Sit back and watch this powerful interview!

Fabled Silver Gold $FCO $FBSGF Spins Out 20+ Copper Occurrences & 3 Classified Deposits Into Fabled Copper Co. $CMMC $NDM $CS $GMBXF

Posted by AGORACOM-Eric at 5:02 PM on Wednesday, May 19th, 2021
This image has an empty alt attribute; its file name is fabled-square.png

VIDEO – PyroGenesis $PYR Now Delivering 3D Printing Powders That “Top Global Aerospace Companies Have Been Waiting For” $MTLS $DDD $SSYS

Posted by AGORACOM-JC at 7:22 PM on Wednesday, May 12th, 2021

PyroGenesis is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products.  In short, their plasma torch technology has been the foundation of multiple successful applications around the world.

One of those applications is ultra high-tech 3D printing powders that earned the company multiple nominations for “Materials Company of the Year” at the 3D Printing Industry Awards as recently as 2019.

Today, PyroGenesis announced “Successful Completion of Additive Manufacturing NexGen™ Powder Test Runs; Commercial Powder Production Begins”


These 2 quotes tell you everything you need to know  

“It is very exciting to know that we are now going to be delivering powders to very discerning and distinguished clients.

With the advantages of the NexGen™ powder production line, we believe it is only a matter of time given the major top tier aerospace companies and OEMs are already awaiting powders from this new state-of-the-art production line.”

“The next step is to complete the qualification processes and secure large long-term contracts, thereby providing PyroGenesis with recurring revenues for years to come.”

Watch our great interview with CEO Peter Pascali .

VIDEO – $ Silicon Production Milestone Moves Company Closer To Awaiting Battery Manufacturers and Automobile Manufacturers HPQFF $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 4:42 PM on Friday, April 23rd, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.  

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following: 

Yesterday, the Company announced a major milestone with this press release HPQ Gen1 Nano Silicon Reactor Exceeds Phase 1 Production Rate Target By 67%

To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:

“Once the final equipment modifications are completed, the goal of the program will be to produce qualified samples which will then be tested by a third-party, the Institut National de Recherche Scientifique (INRS), and subsequently to awaiting battery manufacturers and automobile manufacturers.”

 Peter Pascali, President and CEO of PyroGenesis added a little more excitement when he stated

“It is even more exciting when one considers the impact this could have on addressing the challenges facing the EV battery space.”

Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!

VIDEO – Cardiol Therapeutics $ $CRTPF is a Clinical-Stage Biotech Firm taking on the $30BN Heart Disease Healthcare Market via Cannabidiols and Cutting-Edge Anti-Inflammatory Therapies

Posted by AGORACOM-JC at 4:23 PM on Thursday, April 22nd, 2021

Cardiol Therapeutics $ $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free.

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure.

One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada.

It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart.

  • In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers.

And there’s plenty more to write home about:

  • ~ $27M from exercise of warrants + equity raise since June 2020
  • Uplisting to NASDAQ
  • Team expansion with Chief Medical Officer hire

David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out:

Draganfly $ $DFLYF Announces Record Revenue in Fourth Quarter and Fiscal 2020 Financial Results $ $UAVS $ALPP

Posted by AGORACOM-JC at 9:58 AM on Monday, April 19th, 2021
  • Total revenue for the year ended December 31, 2020, increased by 216.1% to $4.36 million, compared to $1.38 million in 2019

Vancouver, BC., April 19, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“ Draganfly ” or the “ Company ”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce its fourth quarter and fiscal 2020 financial results. Revenue growth for the fourth quarter and the year was driven by a combination of organic growth, the acquisition of Dronelogics Systems Inc. (“ Dronelogics ”), and sales from COVID-19 screening products.

The financial year 2020 was another milestone year for Draganfly. The Company successfully closed and integrated its Dronelogics acquisition which, as planned, became the driver of the bulk of Draganfly new product revenue sales. The Company’s main custom engineering customer effectively shut down this portion of its business in Q1 2020 primarily due to COVID-19; however, services revenues were successfully offset by other drone services work. 2020 revenues were up 216% year over year coming in at $4,363,511 versus $1,380,427 in the previous year. $645,756 represents custom engineering services work, $630,532 represents drone services work and the balance of revenue was from its hardware sales.

The Company recently added health monitoring and prevention to its product and service offering. Securing some key clients in this business line was key to proving out this new vertical. These clients were important for validation of this new technology, but more importantly, it demonstrated the Company’s ability to evolve and offer products and services that have global applicability.

Financial Highlights – 2020:

● Total revenue for the year ended December 31, 2020, increased by 216.1% to $4.36 million, compared to $1.38 million in 2019.

● As a result of increased product sales and service revenue, the Company’s gross profit increased by $597,973, or 51.5%. As a percentage of sales, gross margin ( 1) decreased from 84.1% in 2019 to 40.3% in 2020. This shift in gross margin is due to a higher percentage of hardware sales.

● The Company recorded a comprehensive loss of $8,015,709 compared to a comprehensive loss of $11,095,057 in 2019. The decreased loss was largely the result of the lack of listing expense resulting from the 2019 amalgamation and the funds received from the disposition of an investment that had been previously written off.

● The Company’s cash balance on December 31, 2020, was $1.98 million compared to $2.43 million on December 31, 2019.

For the year ended December 31,   2020  2019 
Total revenues $ 4,363,511 $1,380,427 
Gross Profit (as a % of revenues)   40.3% 84.1%
Net loss   (8,015,813) (11,095,057)
Net loss per share ($)     
– Basic   (0.10) (0.23)
– Diluted   (0.10) (0.23)
Comprehensive loss   (8,015,709) (11,095,057)
Comprehensive loss per share ($)     
– Basic   (0.10) (0.23)
– Diluted   (0.10) (0.23)
Change in cash and cash equivalents   (447,063) 2,349,954 
Total assets   7,100,567  3,221,783 
Working capital   1,214,371  2,037,906 
Total non-current liabilities   104,885  93,073 
Shareholder’s equity (deficiency) $ 3,848,205 $2,191,353 
Number of shares outstanding   86,093,361  69,670,613 

Financial Highlights – Fourth Quarter 2020: 

● Revenue for Q4 2020, increased by 202.3% to $1.49 million, compared to $492 thousand for Q4 2019. The substantial increase in revenue is largely due to the Company’s acquisition of Dronelogics and the retail sales and services business that the acquisition brought partially offset by a decrease in custom engineering services due to the downturn caused by COVID-19. 

● Gross margin percentage for Q4 2020 was 22.2% compared to 91.4% in Q4 2019. The decrease is due to the sales mix as product sales tend to have a much lower margin than those of custom engineering services. 

●Total comprehensive loss for the Q4 2020, was $3.74 million compared to $2.03 million for the same period in 2019. The increase was due to higher office and miscellaneous expenses. 

  2020 Q4 2020 Q3 2019 Q4
Revenue$1,486,009 $1,453,905 $491,520 
Cost of goods sold$(1,155,491)$(893,441)$(42,401)
Gross profit$330,518 $560,464 $449,119 
Gross margin – percentage 22.2% 38.5% 91.4%
Operating expenses$(3,359,508)$(2,852,003)$(2,983,115)
Operating loss$(3,028,990)$(2,291,539)$(2,533,996)
Operating loss per share – basic$(0.04)$(0.03)$(0.04)
Operating loss per share – diluted$(0.04)$(0.03)$(0.04)
Other income (expense)$(713,885)$91,228 $506,080 
Comprehensive loss$(3,741,640)$(2,201,543)$(2,027,916)
Comprehensive loss per share – basic$(0.05)$(0.03)$(0.03)
Comprehensive loss per share – diluted$(0.05)$(0.03)$(0.03)

Cameron Chell, CEO of Draganfly, said: “We have seen tremendous growth in the first quarter of 2021 around some key initiatives including education, military, security, mining, telehealth, and our 24hr pathogen sequestration and kill sanitizing spray applied via patented drone technology. The Draganfly team is looking forward to continuing to build on those relationships, technologies, and innovations.” 

Q4 2020 and Q1 2021 milestones include the following: 

● Secured $1 MM flight services contract to deploy EagleEye ™ AI flight services with Windfall Geotek Inc. Windfall Geotek flies mining prospect with magnetometers with data placed into EagleEye ™ and provides recommended targets for mining companies to drill. 

● Raised US$16,450,000 million through the issuance of securities under the Company’s Regulation A offering filed with the U.S. Securities and Exchange Commission. 

● Entered into an agreement with Southern Alberta Institute of Technology to advance UAV delivery technology, which will include (i) designing, developing, and testing of a cargo system for medical delivery to be ‎mounted on a variety of drones including VTOL rotary and fixed-wing platforms, (ii) developing test protocols, operational procedures, and standards for Beyond Visual ‎Line of Sight medical delivery operation within the framework of ‎Transport Canada, US Federal Aviation Agency, and European ‎Union Aviation Safety Agency procedures and protocols and (iii) developing an operational manual for BVLOS operation of heavy lifting and long ‎endurance RPASS to be used for commercial application under an Air ‎Operator’s Certificate. ‎ 

● Partnership with Steve Wozniak’s K-12 program Woz ED to be the exclusive supplier of drones to Woz ED’s drone program across its ‎national K-12 curriculum and received orders for the sale of 2,000 drones. To clarify the Company’s news release dated March 2, 2021, the Company entered into a memorandum of understanding with Woz ED with the objective to create the terms and conditions surrounding a business agreement. The memorandum of understanding automatically terminates after 60 days; however, the Company anticipates entering into a definitive agreement with Woz ED during Q2 2021.

● Talladega College implemented Vital Intelligence Smart Vital assessment platform, Vital Signs Assessment Stations, and Social Distancing awareness technologies to be used campus-wide to detect potential symptoms of COVID-19.

● Portage County Sheriff’s Department deployed Vital Intelligence Technology to be used to pre-screen inmates and detainees before bringing them into detention.

● Barrett-Jackson Auction Company implementing Draganfly’s Safely Opening Sites protocol for its March 2021 collector car auction in Scottsdale, AZ. including patented drone technology of the Varigard one-of-a-kind, revolutionary organic sanitizer that provides up to 24-hour of pathogen sequestration and kill-efficacy.

● Design and deliver Vital Intelligence technology into The 517 Group’s Hospitality and Entertainment Service Organization.

● Selected by Coldchain Technology Services, LLC (“ Coldchain ”) to develop and provide flight services for drone delivery of the COVID-19 vaccine. To clarify the Company’s news release dated December 22, 2020, the Company entered into a letter of intent with Coldchain with the objective to create the terms and conditions surrounding a business agreement for the development of a vaccine delivery payload system and associated flight services. The letter of intent automatically terminates after 90 days; however, the Company anticipates entering into a definitive agreement with Coldchain during Q2 2021.

● Providing engineering and development services for drone-based air support defense system for Integrated Launcher Solutions (“ ILS ”). To clarify the Company’s news release dated January 21, 2021, the Company entered into a memorandum of understanding with ILS with the objective to create the terms and conditions surrounding a project management and development agreement for the production of ILS’s multi-launching air support defense system. The memorandum of understanding automatically terminates after 60 days; however, the Company anticipates entering into a definitive agreement with ILS during Q2 2021.

● Draganfly selected by Knightscope to integrate mobile Vital Sign Screening technology into its autonomous security robots.

● Issued new delivery drone patent for variable center of gravity vertical take-off and landing aircraft. US Patent No. 10,807,707 is an unmanned aircraft system (UAS) configured for both vertical take-off and landing (VTOL) and fixed-wing flight operations includes forward, and aft wing assemblies mounted to the fuselage, each wing assembly including port and starboard nacelles terminating in motor-driven rotors powered by an onboard control system capable of adjusting rotor speeds.

● Closed an acquisition of assets from Vital Intelligence ‎‎Inc. on March 25, 2021, in consideration for (a) a cash payment of $500,000 with ‎‎$250,000 paid at closing and ‎‎‎$250,000 to be paid on the six-month anniversary date of ‎closing; and (b) ‎6,000,000 units of the ‎‎Company with each unit being comprised of one common share of the Company and one common share ‎‎purchase warrant. The units are subject to ‎‎escrow with 1,500,000 units released at closing and the remainder to be released ‎‎upon the Company reaching certain revenue milestones received from the purchased assets. Each warrant entitles the holder to acquire one common share for a period of 24 ‎months at an exercise price of $2.67 per common share and the Company can accelerate the ‎expiry date of the warrants after one year in the event the underlying common shares ‎have a value of at ‎least 30% greater than the exercise price of the warrants.

All financial information in this press release is prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. The Company will file its consolidated financial statements for the year ended December 31, 2020, and associated management discussion and analysis under the Company’s profile on SEDAR at .

Note 1: this press release refers to “gross margin” which does not have any standardized meaning prescribed by generally accepted accounting principles in Canada (” GAAP “). Gross margin is defined as gross profit divided by revenue and is often presented as a percent. Draganfly’s management believes that gross margin and other non-GAAP measures provide useful information to investors as it provides them with ‎supplemental measures of the Company’s operating performance and liquidity and thus highlights trends in the Company’s ‎business that may not otherwise be apparent when relying solely on GAAP measures. Management also uses non-GAAP measures and ‎metrics in order to facilitate operating performance comparisons from period to period, to prepare ‎annual operating budgets and forecasts and to determine components of executive compensation. For more information with respect to financial measures which have not been defined by GAAP, including reconciliations to the closest comparable GAAP measure, see the “Non-GAAP Measures and Additional GAAP Measures”‎ section of the Company’s most recent MD&A which is available on SEDAR.

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software, and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at .
For additional investor information, visit https:// inc , https:// or https:// draganfly -inc .

Media Contact
Arian Hopkins
Email: [email protected]

Company Contact
Cameron Chell, CEO
PH: 310-658-4413
Email: [email protected]

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.